Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HUTCHMED (China)HMDCF 64 EBIT per Share is $0.57 as of Dec. 2025. GuruFocus rates HMDCF with a GF Score™ of 64/100 and a GF Value™ of $3.76 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 809 Drug Manufacturers companies, HUTCHMED (China) ranks better than 91.22% on this metric.
HUTCHMED (China)'s EBIT per Share for the
six
months ended in Dec. 2025 was $0.58.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.57.
During the past 3 years, the average EBIT per Share Growth Rate was 57.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for HUTCHMED (China)'s EBIT per Share or its related term are showing as below:
HMDCF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -295.8 Med: -32.9 Max: 57.1
Current: 57.1
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of HUTCHMED (China) was 57.10% per year. The lowest was -295.80% per year. And the median was -32.90% per year.
HMDCF's 3-Year EBIT Growth Rate is ranked better than 91.22% of 809
companies
in the Drug Manufacturers industry
Industry Median: 7.5
vs HMDCF: 57.10
HUTCHMED (China) (OTCPK:HMDCF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
HUTCHMED (China) EBIT per Share Related Terms
HUTCHMED (China) EBIT per Share Historical Data
* Premium members only.
The historical data trend for HUTCHMED (China)'s EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HUTCHMED (China) (HMDCF) has a EBIT per Share of $0.57 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HUTCHMED (China) and its competitors. According to the industry distribution chart, HUTCHMED (China) ranks #71 out of 809 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is HUTCHMED (China)'s EBIT per Share too high?
HUTCHMED (China)'s current EBIT per Share is $0.57. The Drug Manufacturers industry median EBIT per Share is 7.50. HUTCHMED (China)'s value of $0.57 is 92.4% below this industry median. Based on the distribution chart, HUTCHMED (China) ranks #71 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HUTCHMED (China) has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HUTCHMED (China)'s EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HUTCHMED (China) ranks #71 out of 809 companies for EBIT per Share. This places HUTCHMED (China) in the top 9% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 7.50. HUTCHMED (China)'s value of $0.57 is 92.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.50, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HUTCHMED (China)'s current EBIT per Share of $0.57 is 92.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on HUTCHMED (China) and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HUTCHMED (China)'s current EBIT per Share is $0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HUTCHMED (China) stock overvalued right now?
Based on GuruFocus' analysis, HUTCHMED (China) (HMDCF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.76, compared to a current price of $2.16 — trading 42.6% below its estimated fair value. The current EBIT per Share is $0.57 and 92.4% below the Drug Manufacturers industry median of 7.50. HUTCHMED (China)'s overall GF Score™ is 64/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For HUTCHMED (China) (HMDCF), the current EBIT per Share is $0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HUTCHMED (China) (HMDCF) Overvalued in 2026?
Based on GuruFocus' analysis, HUTCHMED (China) stock appears to be undervalued.
The current stock price of $2.16 is trading 42.6% below its estimated GF Value™ of $3.76.
GuruFocus considers HUTCHMED (China) to be Possible Value Trap.
Key valuation signals for HMDCF:
EBIT per Share: $0.57
GF Value™: $3.76 vs. price of $2.16 (42.6% below fair value)
Industry Position: 92.4% below the Drug Manufacturers median (#71 of 809)
No single metric tells the full story. See the HMDCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
64GF Score
Get the complete analysis for HMDCF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HMDCF has been successfully added to your 
